Glucagon-like peptide-1 levels and dipeptidyl peptidase-4 activity in type 2 diabetes
Glucagon-like peptide-1 levels and dipeptidyl peptidase-4 activity in type 2 diabetes
thumbnail.default.placeholder
Tarih
2017-01-01
Yazarlar
Senyigit, Abdulhalim
Tabak, Omur
Orbanoglu, Timur
Karadag, Aytac
Ugurlu, Serdal
Uzun, Hafize
Konukoglu, Dihlar
Süreli Yayın başlığı
Süreli Yayın ISSN
Cilt Başlığı
Yayınevi
CANADIAN SOC CLINICAL INVESTIGATION
Dergi Adı
CLINICAL AND INVESTIGATIVE MEDICINE
Özet
Purpose: Hyperglycemia is the major risk factor for microvascular complications in type 2 diabetes mellitus (T2DM) patients. This randomized controlled clinical trial aimed to investigate T2DM patients with microvascular complications with regard to possible relations among serum clusterin (CLU), amylin, secreted frizzled-related protein-4 (SFRP-4), glucagon-like peptide-1 (GLP-1) and dipeptidyl peptidase-4 (DPP-4) activities. Methods: Subject groups were defined as follows: T2DM without complications (n=25, F/M=9/16, age 53.9 +/- 11.1 years)
T2DM+Retinopathy (n=25, F/M=13/12, age 63.8 +/- 7.1 years)
T2DM+Nephropathy (n=25, F/M=13/12, age 58.7 +/- 14.4 years)
T2DM+Neuropathy (n=25, F/M=15/10, age 63.2 +/- 9.6 years)
and healthy control subjects (HC) (n=25). CLU, amylin, SFRP-4, DPP-4 and GLP-1 (total and active) activities were measured and compared in blood samples from type 2 diabetic patients with and without microvascular complications. Results: Significantly lower levels of DPP-4 and GLP-1total (P<0.005 and P<0.001, respectively) and higher levels of SFRP-4 were measured in subjects with T2DM in comparison with HC (P<0.05). Serum CLU, amylin and GLP-1active levels were similar between HC and T2DM patients. Patients with T2DM+microvascular complications had significantly higher DPP-4 and GLP-1total levels when compared with T2DM patients without complications (P<0.05 and P<0.001, respectively). Regardless of the other features, in all patients with T2DM-associated microvascular complications, a positive correlation was evident between DPP-4 activity and GLP-1total (r=0.290
P<0.01). Conclusions: DPP-4 activity and GLP-1total levels were higher in patients with microvascular complications associated with T2DM. Contrary to expectations, no negative correlation was seen between GLP-1 and DDP-4 levels. This result suggests the possible inefficacy of DDP-4 activity as a marker to predict in vivo degradation of endogenous GLP-1.
T2DM+Retinopathy (n=25, F/M=13/12, age 63.8 +/- 7.1 years)
T2DM+Nephropathy (n=25, F/M=13/12, age 58.7 +/- 14.4 years)
T2DM+Neuropathy (n=25, F/M=15/10, age 63.2 +/- 9.6 years)
and healthy control subjects (HC) (n=25). CLU, amylin, SFRP-4, DPP-4 and GLP-1 (total and active) activities were measured and compared in blood samples from type 2 diabetic patients with and without microvascular complications. Results: Significantly lower levels of DPP-4 and GLP-1total (P<0.005 and P<0.001, respectively) and higher levels of SFRP-4 were measured in subjects with T2DM in comparison with HC (P<0.05). Serum CLU, amylin and GLP-1active levels were similar between HC and T2DM patients. Patients with T2DM+microvascular complications had significantly higher DPP-4 and GLP-1total levels when compared with T2DM patients without complications (P<0.05 and P<0.001, respectively). Regardless of the other features, in all patients with T2DM-associated microvascular complications, a positive correlation was evident between DPP-4 activity and GLP-1total (r=0.290
P<0.01). Conclusions: DPP-4 activity and GLP-1total levels were higher in patients with microvascular complications associated with T2DM. Contrary to expectations, no negative correlation was seen between GLP-1 and DDP-4 levels. This result suggests the possible inefficacy of DDP-4 activity as a marker to predict in vivo degradation of endogenous GLP-1.